Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT06307262
Recruiting Observational

European Registry of Transcatheter Repair for Tricuspid Regurgitation

NCT06307262 · tracked via the Priya Life Science Germany tracker
Sponsor
LMU Klinikum
Phase
Observational
Started
2023-10-23
Last updated
2024-03-15

Condition(s) studied

Tricuspid RegurgitationValvular Heart DiseaseHeart Failure

Investigational drug(s) / intervention(s)

T-TEER

T-TEER: T-TEER using the PACAL or TriClip device

Study summary

To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve * Age ≥ 18 years

Primary outcome measure(s)

  • All-cause mortality — 5 years

Trial sites (1)

FacilityCityRegionStatus
LMU Klinikum Munich Bavaria Recruiting

More LMU Klinikum trials in Germany

Global Registry and Natural History Study for Mitochondrial Disorders Recruiting
Tendyne European Experience Registry Recruiting
Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population Recruiting
TRICuspid Intervention and Invasive Hemodynamic Monitoring in Heart Failure Recruiting
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders Enrolling by invitation

Other trials for the same condition

Early Feasibility Study of the Edwards APTURE Transcatheter Shunt System Recruiting
A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants Recruiting
Transcatheter Repair of Tricuspid Regurgitation With Edwards Cardioband TR System Post Market Study (TriBAND) Active, not recruiting
A Study on Remote Health Support for Patients With Heart Failure. Starting soon
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06307262 on ClinicalTrials.gov ↗ ← All trials in Germany